SC
MLTX icon

Stempoint Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History

Stempoint Capital’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-500
Closed -$335K – 84
2023
Q4 		$335K Buy
+500
New +$25.8K 0.09% 65

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Stempoint Capital's MLTX Position: Q1 2026 in Review

Stempoint Capital sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2026, closing a stake of 348,401 shares — an estimated $4.59M sold.

Stempoint Capital first reported a position in MLTX in Q4 2023 and held it in 3 quarters. The position peaked at $10.1M in Q4 2023. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Stempoint Capital reported no remaining MoonLake Immunotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Stempoint Capital sold 348,401 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $4.59M.
  • Stempoint Capital first reported a position in MoonLake Immunotherapeutics in Q4 2023 and held it in 3 quarters.
  • Stempoint Capital's MoonLake Immunotherapeutics position peaked at $10.1M in Q4 2023.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.